Intersection between Clinical Evaluation, Tech Companies & Regulatory

Dr.-Ing. Dr.med.univ.

Johannes Starlinger



Tech Company R

Regulatory

Clinical Evaluation

	Tech Company		Regulatory	Clinical Evaluation
āsk	Claim	Build Al	Deklare	Proove

Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
arlinger 3-CE				
Johannes Starlinger Al4Health WG-CE 10/2020				
Joha A14H 10/2(

Tech Company


Regulatory

Clinical Evaluation

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When				
Why				
What				
Where				
Who				
Johannes Starlinger AI4Health WG-CE 10/2020				

Idea

Tech Company



johannes@starlinger.plus - AI4Health WG-CE 2020

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When				
Why				
What				
Where				
Who				
Johannes Starlinger AI4Health WG-CE 10/2020				

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?		
Why				
What				
Where				
Who				
Johannes Starlinger Al4Health WG-CE 10/2020				

Climia al Estado atta

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?		
Why	Which benefit(s)?	Which outcomes?		
What				
Who				
Johannes Starlinger Al4Health WG-CE 10/2020				

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?		
Why	Which benefit(s)?	Which outcomes?		
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?		
Where				
Who				
Johannes Starlinger Al4Health WG-CE 10/2020				

	Tech Company		Regulatory	Clinical Evalua
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?		
Why	Which benefit(s)?	Which outcomes?		
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?		
Where	Which devices? Which market?	Which input? Which populations? How many datasets?		
Who				
Johannes Starlinger AI4Health WG-CE 10/2020				

Evaluation

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?		
Why	Which benefit(s)?	Which outcomes?		
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?		
Where	Which devices? Which market?	Which input? Which populations? How many datasets?		
Who	Which user/customer?	Explainability?		
Johannes Starlinger Al4Health WG-CE 10/2020				

Regulatory Domains

• Data Privacy → GDPR, HIPAA, other, none

• Health Risk → MDD / MDR, FDA, other, none

• Health Benefit \rightarrow EBM / Clinical Practice Guidelines, none

Regulatory Domains

• Data Privacy → GDPR, HIPAA, other, none

• Health Risk \rightarrow MDD / MDR, FDA, other, none


• Health Benefit \rightarrow EBM / Clinical Practice Guidelines, none

Idea

Intended Use Idea


Classification Intended Use Idea






Tech Company

+




Tech Company

+




Tech Company

+




Tech Company

+



	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?		
Why	Which benefit(s)?	Which outcomes?		
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?		
Where	Which devices? Which market?	Which input? Which populations? How many datasets?		
Who	Which user/customer?	Explainability?		
Johannes Starlinger Al4Health WG-CE 10/2020				

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?	Indications & Contraind. Patient characteristics	
Why	Which benefit(s)?	Which outcomes?	Benefit	
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?	Performance specification Risk & Classification	
Where	Which devices? Which market?	Which input? Which populations? How many datasets?	Device & input compatibility Target market	
Who	Which user/customer?	Explainability?	Users & Use context	
Johannes Starlinger Al4Health WG-CE 10/2020				





Requirements for (Al as) SaMD

- Proof of benefit and performance
- Verification and validation
- Assertion of reproducibility and reliability of results
- Description of methods and metrics used for the above

Assertion of competence of involved personnel



Requirements for (Al as) SaMD

Clinical Evaluation!


- Proof of benefit and performance
- Verification and validation



Description of methods and metrics used for the above

Assertion of competence of involved personnel





	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?	Indications & Contraind. Patient characteristics	
Why	Which benefit(s)?	Which outcomes?	Benefit	
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?	Performance specification Risk & Classification	
Where	Which devices? Which market?	Which input? Which populations? How many datasets?	Device & input compatibility Target market	
Who	Which user/customer?	Explainability?	Users & Use context	
Johannes Starlinger Al4Health WG-CE 10/2020				

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?	Indications & Contraind. Patient characteristics	Patient cohort characteristics
Why	Which benefit(s)?	Which outcomes?	Benefit	Defined endpoints
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?	Performance specification Risk & Classification	Evaluation metrics PICOs
Where	Which devices? Which market?	Which input? Which populations? How many datasets?	Device & input compatibility Target market	Included devices Study centers Countries
Who	Which user/customer?	Explainability?	Users & Use context	Study personnel
Johannes Starlinger AI4Health WG-CE 10/2020				

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?	Indications & Contraind. Patient characteristics	Patient cohort characteristics
Why	Which benefit(s)?	Which outcomes?	Benefit	Defined endpoints
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?	Performance specification Risk & Classification	Evaluation metrics PICOs
Where	Which devices? Which market?	Which input? Which populations? How many datasets?	Device & input compatibility Target market	Included devices Study centers Countries
Who	Which user/customer?	Explainability?	Users & Use context	Study personnel
Johannes Starlinger Al4Health WG-CE 10/2020	New market! New indication! New device!	More data? Other data? Other populations? New model?	Changes in - performance - input / types of input - intended use	Snapshot + Continuous? Drift?

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?	Indications & Contraind. Patient characteristics	Patient cohort characteristics
Why	Which benefit(s)?	Which outcomes?	Benefit	Defined endpoints
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?	Performance specification Risk & Classification	Evaluation metrics PICOs
Where	Which devices? Which market?	Which input? Which populations How many datasets?	Device & input compatibility Target market	Included devices Study centers Countries
Who	Which user/customer?	Explainability?	Users & Use context	Study personnel
Johannes Starlinger Al4Health WG-CE 10/2020	New market! New indication! New device!	More data? Other data? Other populations? New model?	Changes in - performance - input / types of input - intended use	Snapshot + Continuous? Drift?

	Tech Company		Regulatory		Clinical Evaluation
Task	Claim	Build Al	Deklare	Does the po	opulation
Theme	Business Strategy	Data Availability	Intended U	match the da	ita <u>on site</u> ?
When	Which indication(s)? e.g., which diseases	Which patients' data?	Indications Patient cha	Does the stud	CS
Why	Whi Is the population	in a outcomes?	Benefit	target pope	Detinea endpoints
What	Whi target market diffe		Performance Pick & Classif	•	Evaluation metrics PICOs
Where	Which devices Which market?	Which input? Which populations How many datasets	Device & inputompatibility Target market		ncluded devices Study centers Countries
Who	Which user/customer?	Explainability?	Users & Use of	context	Study personnel
Johannes Starlinger Al4Health WG-CE 10/2020	New market! New indication! New device!	More data? Other data Other population New model?	the data?	ce es of input se	Snapshot + Continuous? Drift?

	Tech Company		Regulatory		Clinical Evaluation	
Task	Claim	Build Al	Which sites can perform the evaluation? Do we have their populations covered?			Proove
Theme	Business Strategy	Data Availabilit				Study Design
When	Which indication(s)? e.g., which diseases	Which patients'				Patient cohort characteristics
Why	Which benefit(s)?	Which outcome			Defined endpoints	
What	Which application?	Which models? Which features? Which metrics? Which risks & m		Performance spec		Evaluation metrics PICOs
Where	Which devices? Which market?	Which input? Which population How many data		Device & input compatibility Target market		ncluded devices Study centers Countries
Who	Which user/customer?	Explainability?		Users & Use conte	ext	Study personnel
Johannes Starlinger Al4Health WG-CE 10/2020	New market! New indication! New device!	More data? Other data? Other population New model?	ns?	Changes in - performance - input / types of - intended use	input	Snapshot + Continuous? Drift?

	Tech Company		Regulatory	Clinical Evaluation
Task	Claim	Build Al	Deklare	Proove
Theme	Business Strategy	Data Availability	Intended Use	Study Design
When	Which indication(s)? e.g., which diseases	Which patients' data?	Indications & Contraind. Patient characteristics	Patient cohort characteristics
Why	Which benefit(s)?	Which outcomes?	Benefit	Defined endpoints
What	Which application?	Which models? Which features? Which metrics? Which risks & mitigations?	Performance specification Risk & Classification	Evaluation metrics PICOs
Where	Which devices? Which market?	Which input? Which populations? How many datasets?	Device comportant aspect	ts a selection
Who	Which user/customer?	Explainability?	Users but is non-ext	haustive!
Johannes Starlinger Al4Health WG-CE 10/2020	New market! New indication! New device!	More data? Other data? Other populations? New model?	Changes in - performance - input / types of input - intended use	Snapsnot + Continuous? Drift?

In Healthcare

- Building Al Systems
- Regulatory Conformance
- Clinical Evaluation

influence one another each way!

